Impact of Neointimal Condition and Platelet Reactivity on Intrastent Thrombus at Long-Term Follow-up After 2nd- and 3rd-Generation Drug-Eluting Stent Implantation ― Insights From a Coronary Angioscopy and Pharmacodynamic Study ―
Open Access
- 25 November 2020
- journal article
- research article
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 84 (12), 2244-2252
- https://doi.org/10.1253/circj.cj-20-0796
Abstract
Background:Although the incidence of very late stent failure (VLSF) is reduced with newer generation drug-eluting stent (DES), the mechanism of VLSF has not been fully explored. Methods and Results:This study evaluated both local vascular healing using coronary angioscopy and systemic factors determined by platelet reactivity at long-term follow-up after 2nd- and 3rd-generation DES implantation in patients with acute coronary syndrome. Coronary angioscopy was performed to assess neointimal coverage (NIC), yellow color (YC) grade and presence of thrombus. The obtained findings were compared with 2nd- and 3rd-DES. Platelet aggregation was assessed by light transmittance aggregometry. 100 consecutive patients were prospectively enrolled: 2nd- (n=50) and 3rd-DES (n=50). 3rd-DES patients had significantly higher NIC grade and lower YC grade compared with 2nd-DES. The presence of thrombus was tended to be lower with 3rd-DES than with 2nd-DES (8% vs. 18%, P=0.11). Patients with thrombus had significantly higher maximum platelet aggregation and higher prevalence of high on-treatment platelet reactivity (HPR) than those without thrombus. Multivariable analysis showed stent strut exposure and HPR as independent predictors of thrombus. Conclusions:Newer generation DES contribute to better vascular healing depending on the degree of neointimal coverage. In addition to local factors at the stented lesion, systemic factors such as degree of platelet reactivity might also contribute to VLSF.Keywords
This publication has 29 references indexed in Scilit:
- Randomized Comparison of Everolimus- and Paclitaxel-Eluting Stents: 2-Year Follow-Up From the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV TrialJournal of the American College of Cardiology, 2011
- The Pathology of Neoatherosclerosis in Human Coronary Implants: Bare-Metal and Drug-Eluting StentsJournal of the American College of Cardiology, 2011
- Inhibitory Effects of Ticagrelor Compared With Clopidogrel on Platelet Function in Patients With Acute Coronary Syndromes: The PLATO (PLATelet inhibition and patient Outcomes) PLATELET SubstudyJournal of the American College of Cardiology, 2010
- Atherosclerotic and Thrombogenic Neointima Formed Over Sirolimus Drug-Eluting Stent: An Angioscopic StudyJACC: Cardiovascular Imaging, 2009
- Pathological Correlates of Late Drug-Eluting Stent ThrombosisCirculation, 2007
- Drug-Eluting Stent and Coronary ThrombosisCirculation, 2007
- Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery DiseaseCirculation, 2007
- Impact of the Degree of Peri-Interventional Platelet Inhibition After Loading With Clopidogrel on Early Clinical Outcome of Elective Coronary Stent PlacementJournal of the American College of Cardiology, 2006
- Platelet Reactivity in Patients and Recurrent Events Post-Stenting: Results of the PREPARE POST-STENTING StudyJournal of the American College of Cardiology, 2005
- Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting StentCirculation, 2004